Scancell has appointed Samantha Paston, PhD as its new head of research, and Adrian Parry, PhD as head of manufacturing; Dr Paston started in her role in mid-January and Dr Parry will start in his role on 01 February 2019.
Dr Samantha Paston joins Scancell from Immunocore where she has held several positions since June 2008 including head of T Cell Cloning and group leader. While at Immunocore Samantha was responsible for the generation of the in house T cell cloning method and biological molecule discovery which made significant contributions to the current Immunocore oncology pipeline. She holds a PhD from University College London in Immunology/Haematology, following an BSc Honours Degree in Microbiology from the University of Sheffield.
Dr Adrian Parry joins Scancell from Mereo BioPharma where he was head of small molecule CMC (Chemistry, Manufacturing and Controls), managing outsourced GMP manufacturing activities to support their clinical trials. Prior to this, Adrian was new product development director at Juniper Pharmaceuticals where he managed and coordinated preclinical and CMC development activities. He has also previously held further CMC positions at Circassia, Shire Pharmaceuticals, Prosidion, Evotec and OSI Pharmaceuticals, totalling 20 years of development expertise including the delivery of multiple, complex GMP drug products with associated regulatory submissions in Europe and the US.
